ReviewInternational journal of nanomedicine2026
Exosomes as Pivotal Mediators of Tumor-Immune Communication: Implications for Immunotherapy and Liquid Biopsy.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plant-Derived Exosomes Deliver Theranostic Molecules to Target Cells.Nanomaterials (Basel, Switzerland) · 2026Article
- Glioma-derived extracellular vesicles as drivers of immunotherapeutic resistance: mechanisms of immune reprogramming and metabolic intervention.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes are membrane-bound vesicles secreted by almost all types of cells, including but not limited to immune cells, neurons, epithelial cells, and cancer cells. Exosomes carry DNA, RNA, lipids, metabolites, as well as cytoplasmic and cell surface proteins. Their role in cancer progression is dynamic and is related to the type of cancer, genetics, and stage. At the same time, exosomes have attracted widespread attention as key mediators of intercellular communication in the tumor immune microenvironment (TME). This comprehensive review delineates the pleiotropic roles of exosomes in tumor immunobiology, emphasizing their bimodal capacity to either foster immunosuppression or potentiate antitumor immunity. We systematically synthesize recent advancements in exosome-based immunotherapeutic regimens, with particular emphasis on their synergistic efficacy when integrated with established modalities, namely immune checkpoint blockade and adoptive cellular therapy. Furthermore, we critically appraise emergent technologies for exosome isolation and characterization, underscoring their transformative implications for liquid biopsy platforms in real-time immune surveillance and the development of predictive biomarkers. This review posits exosome-centric strategies as a paradigm-shifting frontier in precision immuno-oncology, furnishing innovative remedies for recalcitrant therapeutic hurdles and propelling the advancement of personalized oncology care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.